First-Ever Four-Year MIGS Pivotal Trial Results Show Hydrus Microstent Significantly Reduces Need for Invasive Surgery and Subsequent Glaucoma Medication
February 27, 2020 06:00 ET
|
Ivantis Inc.
IRVINE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for...